<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764061</url>
  </required_header>
  <id_info>
    <org_study_id>TP-CLN-100067</org_study_id>
    <nct_id>NCT01764061</nct_id>
  </id_info>
  <brief_title>Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)</brief_title>
  <official_title>Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haemonetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haemonetics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate that single units of RBCs collected by the&#xD;
      Haemonetics MCS®+ 8150 system using LN832 disposable sets during an interrupted double red&#xD;
      cell collection protocol meet all in vitro FDA requirements for non-leukoreduced red blood&#xD;
      cells, and to provide data to support the 510(k) clearance of the MCS®+ 8150 system using&#xD;
      LN832 disposable sets for this intended use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will take place at two sites (Blood Center of Wisconsin (BCW) Milwaukee, WI and&#xD;
      American Red Cross-Norfolk, VA).&#xD;
&#xD;
        -  A standard double red cell collection protocol will be initiated using the Haemonetics&#xD;
           MCS®+ 8150 system using LN832 disposable sets. The collection procedure will be&#xD;
           terminated after collection of one RBC unit. The maximum target red cell volume will be&#xD;
           selected based on the donor predonation weight as specified in the nomogram included in&#xD;
           the MCS®+ 8150 operation manual.&#xD;
&#xD;
        -  The RBC units will be stored for 42 days at 1° to 6°C.&#xD;
&#xD;
        -  Upon collection and at 42 days after collection, the RBC units will be weighed and&#xD;
           tested for hematology parameters (white blood cell count, red blood cell count, residual&#xD;
           white blood cell count, hemoglobin, hematocrit, platelet count, mean corpuscular volume,&#xD;
           mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cell&#xD;
           distribution width, and supernatant hemoglobin) and chemistry parameters (pH, potassium,&#xD;
           glucose, lactate, and ATP).&#xD;
&#xD;
        -  Acceptance criteria for this study are as follows:&#xD;
&#xD;
             1. Hemolysis of less than or equal to 1% at 42 days of storage&#xD;
&#xD;
             2. Maximum absolute red cell volume is less than or equal to the programmed absolute&#xD;
                RBC target volume + 15%&#xD;
&#xD;
             3. Minimum absolute red cell volume is greater than or equal to the programmed&#xD;
                absolute RBC target volume - 15%&#xD;
&#xD;
        -  After collection of sixty (60) evaluable RBC units, the study will be considered&#xD;
           supportive of the intended use noted above if zero (0) units fail the acceptance&#xD;
           criteria.&#xD;
&#xD;
        -  If one (1) unit fails acceptance criteria after collection of sixty (60) evaluable RBC&#xD;
           units, an additional seventy one (71) units will be collected.&#xD;
&#xD;
        -  The study will be considered supportive of the intended use noted above if not more than&#xD;
           one (1) total unit out of 131 evaluable units fails the acceptance criteria.&#xD;
&#xD;
        -  If a total of two (2) units fail acceptance criteria, the study will not be considered&#xD;
           supportive of the intended use noted above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hemolysis level at 42 days of storage</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute red cell volume</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Red Blood Cell Donation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy blood donors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and Females ≥ 18 years of age&#xD;
&#xD;
          -  Males ≥ 130 pounds, Females ≥ 150 pounds&#xD;
&#xD;
          -  Males ≥ 5 feet, 1 inch, Females ≥ 5 feet, 3 inches&#xD;
&#xD;
          -  Hemoglobin ≥ 13.3 g/dL&#xD;
&#xD;
          -  Hematocrit ≥ 40%&#xD;
&#xD;
          -  Donor Eligibility: Meets all criteria as per sites' Research Blood Donation Record,&#xD;
             Prior donation date (i.e. not less than 112 days for most recent double RBC unit&#xD;
             donation, 56 days for most recent single RBC unit donation)&#xD;
&#xD;
          -  Subject must provide informed consent using an IRB informed consent form prior to&#xD;
             undergoing any study related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  will be not fulfilling any of the inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lou Anne Young Maes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American National Red Cross</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome Gottschall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versiti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American Red Cross</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <last_update_submitted>October 9, 2013</last_update_submitted>
  <last_update_submitted_qc>October 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Red Cells</keyword>
  <keyword>Blood donors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

